BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30357936)

  • 1. Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.
    Trinh J; Zeldenrust FMJ; Huang J; Kasten M; Schaake S; Petkovic S; Madoev H; Grünewald A; Almuammar S; König IR; Lill CM; Lohmann K; Klein C; Marras C
    Mov Disord; 2018 Dec; 33(12):1857-1870. PubMed ID: 30357936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
    Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
    Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDSGene: Closing Data Gaps in Genotype-Phenotype Correlations of Monogenic Parkinson's Disease.
    Klein C; Hattori N; Marras C
    J Parkinsons Dis; 2018; 8(s1):S25-S30. PubMed ID: 30584170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review.
    Kasten M; Hartmann C; Hampf J; Schaake S; Westenberger A; Vollstedt EJ; Balck A; Domingo A; Vulinovic F; Dulovic M; Zorn I; Madoev H; Zehnle H; Lembeck CM; Schawe L; Reginold J; Huang J; König IR; Bertram L; Marras C; Lohmann K; Lill CM; Klein C
    Mov Disord; 2018 May; 33(5):730-741. PubMed ID: 29644727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
    Fernández-Santiago R; Garrido A; Infante J; González-Aramburu I; Sierra M; Fernández M; Valldeoriola F; Muñoz E; Compta Y; Martí MJ; Ríos J; Tolosa E; Ezquerra M;
    Mov Disord; 2018 Apr; 33(4):637-641. PubMed ID: 29473656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SNCA but not DNM3 and GAK modifies age at onset of LRRK2-related Parkinson's disease in Chinese population.
    Yang ZH; Li YS; Shi MM; Yang J; Liu YT; Mao CY; Fan Y; Hu XC; Shi CH; Xu YM
    J Neurol; 2019 Jul; 266(7):1796-1800. PubMed ID: 31041581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapies for Genetic Forms of Parkinson's Disease: Systematic Literature Review.
    Over L; Brüggemann N; Lohmann K
    J Neuromuscul Dis; 2021; 8(3):341-356. PubMed ID: 33459660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of LRRK2 and SNCA in autosomal dominant Parkinson's disease in Turkey.
    Kessler C; Atasu B; Hanagasi H; Simón-Sánchez J; Hauser AK; Pak M; Bilgic B; Erginel-Unaltuna N; Gurvit H; Gasser T; Lohmann E
    Parkinsonism Relat Disord; 2018 Mar; 48():34-39. PubMed ID: 29248340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the genetic variability in Parkinson's disease from Southern Spain.
    Bandrés-Ciga S; Mencacci NE; Durán R; Barrero FJ; Escamilla-Sevilla F; Morgan S; Hehir J; Vives F; Hardy J; Pittman AM
    Neurobiol Aging; 2016 Jan; 37():210.e1-210.e5. PubMed ID: 26518746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age at onset in LRRK2-associated PD is modified by SNCA variants.
    Botta-Orfila T; Ezquerra M; Pastor P; Fernández-Santiago R; Pont-Sunyer C; Compta Y; Lorenzo-Betancor O; Samaranch L; Martí MJ; Valldeoriola F; Calopa M; Fernández M; Aguilar M; de Fabregas O; Hernández-Vara J; Tolosa E
    J Mol Neurosci; 2012 Sep; 48(1):245-7. PubMed ID: 22669510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of Parkinson's disease: a review of SNCA and LRRK2.
    Konno T; Siuda J; Wszolek ZK
    Wiad Lek; 2016; 69(3 Pt 1):328-32. PubMed ID: 27486710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural genomic variations and Parkinson's disease.
    Bandrés-Ciga S; Ruz C; Barrero FJ; Escamilla-Sevilla F; Pelegrina J; Vives F; Duran R
    Minerva Med; 2017 Oct; 108(5):438-447. PubMed ID: 28541025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics of Parkinson disease.
    Domingo A; Klein C
    Handb Clin Neurol; 2018; 147():211-227. PubMed ID: 29325612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson's disease patients.
    Boros FA; Török R; Vágvölgyi-Sümegi E; Pesei ZG; Klivényi P; Vécsei L
    Neurosci Lett; 2019 Jul; 706():140-145. PubMed ID: 31085292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition.
    Kadgien CA; Kamesh A; Milnerwood AJ
    Mol Brain; 2021 Sep; 14(1):143. PubMed ID: 34530877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila.
    Inoshita T; Arano T; Hosaka Y; Meng H; Umezaki Y; Kosugi S; Morimoto T; Koike M; Chang HY; Imai Y; Hattori N
    Hum Mol Genet; 2017 Aug; 26(15):2933-2948. PubMed ID: 28482024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
    Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
    Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants.
    Xiromerisiou G; Hadjigeorgiou GM; Gourbali V; Johnson J; Papakonstantinou I; Papadimitriou A; Singleton AB
    Eur J Neurol; 2007 Jan; 14(1):7-11. PubMed ID: 17222106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.